Embecta Corp. (EMBC)
Embecta Corp. operates in the Medical - Instruments & Supplies industry of the Healthcare sector, headquartered in Parsippany, NJ, US. The stock last traded at $5.21, down 1.42% on the session, giving a market capitalisation of $309.4M. On trailing twelve-month figures it carries a trailing P/E of 3.50, a net margin of 8.6%. Its beta of 0.85 implies it has historically moved less than the broad market.
Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta's headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.
Embecta Corp. is most often compared with the following Healthcare names: